News & Perspective

Aug 12, 2019

Aug 12, 2019
Alima cube

Ebola outbreak treatment trial narrowed to two promising drugs

Officials hope the promising treatment findings encourage more patients to seek lifesaving treatment.

Apr 03, 2019

Apr 03, 2019

News Scan for Apr 03, 2019

Ebola Bombali in Kenyan bats
Universal flu vaccine trial
E coli O103 in 4 states
Lassa fever in Nigeria
Waterborne hospital infections

Feb 12, 2019

Feb 12, 2019

News Scan for Feb 12, 2019

More Saudi MERS cases
Yellow fever in Brazil
Lassa fever in Guinea and Nigeria
Zika in Mexico
Gain-of-function H5N1 studies to resume

Oct 30, 2018

Oct 30, 2018
ebola vaccine

Ebola total hits 276 as lasting effect noted for 3 vaccines

Immune response lasted 2.5 years for the vaccines, the longest yet in ongoing studies of Ebola immunization.

Aug 16, 2018

Aug 16, 2018
vaccine research

CEPI announces new collaboration and funding for Lassa vaccine

The announcement comes as Nigeria is experiencing its largest outbreak, with 481 confirmed cases reported as of last week, 133 of them fatal.

Aug 14, 2018

Aug 14, 2018
IV therapy

DRC Ebola cases surpass earlier outbreak total, virus infects 4 more health workers

The WHO's director-general today warned that 'red zones' in conflict areas could be hiding places for Ebola.

Aug 13, 2018

Aug 13, 2018
Ebola treatment unit

Worries about security and healthcare exposures as DRC Ebola total grows to 52

A WHO official said Ebola spread could get worse before it gets better, due to health worker exposures early in the outbreak.

Jun 28, 2018

Jun 28, 2018

News Scan for Jun 28, 2018

DRC Ebola contacts complete monitoring
Water source in romaine E coli outbreak
Proposed public health corps cuts
Universal flu vaccine initiative

Jan 10, 2018

Jan 10, 2018

News Scan for Jan 10, 2018

Ebola antibody findings
USDA egg product rule
1918 pandemic flu severity

Oct 11, 2017

Oct 11, 2017
Ebola vaccine study

Liberia trial finds Ebola vaccines yield year-long immune response

A trial at the end of Liberia's Ebola outbreak shows 2 candidate vaccines posed no major safety concerns and triggered immune responses that lasted at least a year.

Pages

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»